In man, the major hormones controlling the lipolytic function are insulin (inhibition of lipolysis) and catecholamines (stimulation of lipolysis). Catecholamines are of major importance for the regulation of lipid mobilization in human adipose tissue and for the increase of non-esteri®ed fatty acid supply to the working muscle. In vitro studies have shown that there are differences in the catecholaminergic control of fat cells from various fat deposits and a number of physiological and pathological alterations of catecholamine-induced lipolysis have been reported. Lipolytic resistance to catecholamines has been reported in subcutaneous adipose tissue, the major fat depot in obese subjects. Multiple alterations in catecholamine signal transduction pathways have been reported. In situ microdialysis allows a physiological exploration of adipose tissue biology. Recent data obtained on the catecholaminergic regulation of lipolysis and lipid mobilization, using microdialysis in humans, will be analysed. A potent lipolytic and lipomobilizing effect of atrial natriuretic peptide has recently been discovered; the mechanisms of action and physiological relevance will also be discussed.
Introduction
Hormone-sensitive lipase (HSL) is the rate-limiting enzyme in the hydrolysis of stored triglycerides in adipose tissue and lipolysis regulation. HSL functions together with monoglyceride lipase (MGL), which is required to obtain a complete hydrolysis of the monoglycerides produced by HSL action. 1 In contrast to HSL, MGL is not believed to be under acute hormonal or neural control. Basically, short-term regulation of adipocyte lipolysis is under the control of a number of stimulatory and inhibitory pathways leading to the control of hormone-sensitive lipase (HSL) activity. In human adipocyte, the major hormones controlling the lipolytic function are insulin (inhibition of lipolysis) and catecholamines (stimulation of lipolysis). Insulin is regarded as the most important antilipolytic hormone in mammals. Its ability to antagonize hormoneinduced lipolysis can, to a large extent, be explained by its ability to activate phosphodiesterase 3B and lower cAMP production in fat cells. 2 Catecholamines are of major importance for the regulation of lipid mobilization in human adipose tissue (AT) and for the increase of non-esteri®ed fatty acid (NEFA) supply to the working muscle. The simpli®ed scheme of regulation of HSL activity by catecholamines follows the well-known sequence: the binding of agonists to the b-adrenergic receptors (b-ARs) coupled to adenylyl cyclase via the stimulatory Gs protein, increment of cAMP production which leads to activation of protein kinase A (PKA) and phosphorylation of HSL, resulting in increased enzyme activity and NEFA and glycerol release by fat cells. HSL-derived fatty acids are bound by adipocyte lipid-binding protein (ALBP) to facilitate intracellular traf®cking of hydrophobic lipids. Until recently, HSL activation was believed to be exerted via the phosphorylation of a serine residue, Ser-563 (corresponding to Ser-552 in human HSL), by PKA. Another site known to be phosphorylated by cAMP-independent mechanisms in non-stimulated adipocytes, Ser-565 (corresponding to Ser-554 in human HSL), does not appear to directly affect enzyme activity. This site, often referred to as the basal site, is presumably phosphorylated by the 5 H AMP-activated protein kinase and prevents subsequent phosphorylation of HSL by PKA. Two novel sites, Ser-659 and Ser-660, which are phosphorylated both in vivo in response to a b-adrenergic stimulation and in vitro by PKA, represent new candidates for HSL activation in rat fat cells. 3 The role of the corresponding putative sites requires demonstration in human fat cells. Recent data also suggest that in addition to PKA other kinases may also be involved in the activation of HSL.
It is clear that HSL regulation is under the potent control of cAMP and PKA. In human fat cells, adenylyl cyclase activity and cAMP production are under the concomitant control of positive b 1 -, b 2 -and b 3 -AR-dependent stimulation and a 2 -AR-mediated inhibition. In vitro studies on human fat cells have clearly shown that the ®ne tuning of cAMP levels and lipolysis by catecholamines is dependent on the crosstalk between b-and a 2 -AR-dependent pathways. The level of expression and the repertoire of human fat cell ARs largely differ according to the sex, the anatomical location and the size of fat deposits, and the age of the subjects. The variable af®nities of the various band a 2 -AR subtypes for catecholamines could explain the differential receptor recruitment assessed in a number of in vitro studies. Usually, fat cells from visceral deposits exhibit the highest b-adrenergic and the lowest a 2 -adrenergic responsiveness. 4 In vitro studies have suggested that there is lipolytic resistance to catecholamines in human subcutaneous AT, the major fat depot in obese subjects. 5, 6 Multiple alterations in catecholamine signal transduction pathways, involving decreased expression and function of b 2 -ARs, increased expression and function of a 2 -AR, decreased ability of cAMP to stimulate HSL andaor reduced expression of the enzyme have been reported. The regulation of lipolysis in vitro is complex because of the heterogeneity of fat cell a 2 -ab-AR adrenoceptor ratio according to AT location. Interindividual variations in catecholamine-induced lipolysis are of importance for the rate of weight loss. Concomitant variations in b 2 -AR and a 2 -AR sensitivity in adipocytes may be predictive of weight loss during treatment with very-low-energy diets. Tissue-speci®c investigations, using in situ microdialysis, are necessary to establish the physiological relevance of a large number of in vitro data.
Hormone-sensitive lipase function and beta-adrenoceptor-mediated stimulation of lipolysis
The activity of the sympathetic nervous system (SNS) is related to the three major components of energy expenditure, that is, resting metabolic rate, thermic effect of food and spontaneous physical activity. It is considered that a low activity of the SNS is associated with the development of obesity in rodents and humans. Alterations of SNS signalling at the target cell level (eg the fat cell being one of the privileged targets), could have a major effect on metabolic events controlled by the SNS, especially lipolysis and thermogenesis. The b 2 -AR is a major lipolytic receptor in human fat cells while the physiological role of the b 3 -AR remains questionable, although some drugs, considered b 3 -agonists, have been shown to exert lipolytic effects in human omental fat cells. Various forms of treatment of obesity such as low-and very-low-energy diets and physical activity remain widely used therapies to promote weight reduction in obese patients. Alterations of the lipolytic responses affecting HSL expression and function and b-AR-mediated events have recently been described on human isolated fat cells in vitro or when using in situ microdialysis in patients submitted to such therapies ( Table 1) . Comparison of subcutaneous adipocytes, with identical sizes but exhibiting high and low lipolytic capacity, has revealed that HSL activity and quantity is the lowest in the low lipolytic responders. HSL expression, measured either as total HSL protein by Western blot analysis or as total amount of HSL activatable enzyme, is a major determinant of the maximum lipolytic capacity of human fat cells. 7 Moderate weight loss leads to improved adipose cell lipolytic ef®ciency, which is associated with changes HSL, hormone-sensitive lipase.
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at receptor levels (increased b2-and decreased a2-AR sensitivities). 8 Hereditary in¯uences have been reported in catecholamine-induced lipolysis. 9 ± 11 Recent genetic studies have shown the involvement of genes encoding components of the lipolytic pathways in obesity. The HSL locus was associated with obesity and NIDDM in two independent studies, suggesting that the HSL gene could represent a susceptibility gene for both disorders. 12 A number of studies have tested whether known polymorphisms in codons 64 for the b 3 -AR and 16, 27 and 164 for the b 2 -AR play a role in the control of the lipolytic function of adipocyte and have an incidence on the development of obesity-related metabolic disorders. A missense mutation of b 3 -AR gene (Trp64Arg) has been reported to be associated with high BMI, abdominal obesity, increased capacity to gain weight and resistance to insulin and early onset of non-insulin-dependent diabetes mellitus (NIDDM). For the moment a number of controversial studies have been reported and it is dif®cult to reach a ®nal conclusion. 13 Some studies have shown that the polymorphism is associated with obesity and altered b 3 -AR function while others did not show any phenotypic effect of the polymorphism.
The b 2 -AR, Thrl64Ile substitution, leading to alteration of b-AR coupling and function, was not detected in the subjects studied. In a group of 140 women with a large variation in body fat mass, the Gln27Glu substitution was twice as common in obese subjects as in non-obese; homozygotes for Glu27Glu had an average fat mass excess of 20 kg and approximately 50% larger fat cells than controls. 9, 14 However, no signi®cant association with changes in b 2 -AR function was observed. The frequency of the Glu27 is also higher in patients with NIDDM, but this association could be secondary to obesity. The polymorphisms in codons 16 and 27 are in a strong linkage disequilibrium, as two-thirds of the women investigated carried at the same time Gly16 and Glu27 in a hetero-or homozygous form. The Arg16Gly polymorphism was associated with altered b 2 -AR function, with Gly16 carriers showing a 5-fold increased agonist sensitivity and without any change in b 2 -AR expression. The frequency of Gly16 homozygotes was lower in obese women when compared with nonobese. A recent population study on 1195 subjects of the WHO-MONICA project in the North of France has shown that men bearing the Gln27Gln genotype had higher body weight, body mass index and waist ± hip ratio and increased risk of obesity; the effect, mainly detected in men, is independent of the Gly16Arg polymorphism (Meirhaeghe, 1999, personal communication) . Physical activity counterbalanced the effect of the genetic predisposition to increase body weight, body fat and obesity described in Gln27Gln subjects. Obese individuals with the b 2 -AR Gln27Gln genotype may bene®t from physical activity to reduce their weight. 15 These ®ndings suggest that polymorphisms in the coding sequence in the human bAR-2 gene could be of major importance for obesity, energy expenditure and b 2 -AR-dependent lipolytic function in AT. It should be noticed that, in human fat cells, any reduction of the b 2 -AR-mediated lipolytic response will disturb the functional balance between a 2 -and b 2 -AR-mediated effects and amplify the reduction of the lipolytic response initiated by the physiological amines.
Physiological activation of fat cell a a 2 -adrenoceptors and alterations of lipid mobilization
The regulation of lipolysis in vitro is complex because of the heterogeneity of fat cell a 2 -ab-AR adrenoceptor ratio according to AT location. The coexistence of lipolytic b-ARs and antilipolytic a 2 -ARs in human fat cells has been largely demonstrated through in vitro studies on isolated fat cells and binding studies. The rate of lipolysis Ð through activation or inhibition of adenylyl cyclase Ð is relevant from this dual action of catecholamines on lipolysis. In human subcutaneous fat cells where a 2 -ARs numerically predominate over b-ARs, the recruitment of the a 2 -ARs, leading to epinephrine inhibition of lipolysis, has been described in vitro. Epinephrine is the preferential amine for fat cell a 2 -adrenoceptors, suggesting that it is probably involved more than norepinephrine in the control of lipolysis through the a 2 -adrenergic pathway. The physiological relevance of such in vitro a 2 -AR responsiveness to catecholamines is not clearly understood and has been questioned several times. Interindividual and anatomical variations in catecholamine-induced lipolysis are of importance for the rate of weight loss. In vitro studies have shown that concomitant variations in b 2 -AR and a 2 -AR sensitivity in adipocytes may be predictive of weight loss during treatment with dieting or very-low-energy diets. 8, 16 Whatever the mechanistic interest of the in vitro approaches, tissue-speci®c investigations, using in situ microdialysis, are necessary to settle the physiological relevance of a large number of in vitro studies and the signi®cance of a 2 -AR-mediated pathways.
The putative physiological relevance of a 2 -ARs has recently been investigated more deeply by our group. Exercise was selected as a perequisite to activate the SNS and promote increment of circulating catecholamines in man. The aim of our studies was: (1) to reveal the consequences of a physiological activation of fat cell b-aa 2 -ARs in subcutaneous AT in normal subjects performing exercise, and (2) to delineate the importance of a 2 -AR-mediated pathways in the AT of obese subjects during exercise.
The ®rst study, in which the aim was to determine the involvement of the antilipolytic a 2 -adrenergic pathway and the speci®c role of epinephrine in the control of lipolysis during exercise in AT, was performed on healthy male subjects. An in vitro study carried out on isolated adipocytes showed that the weak lipolytic effect of epinephrine was potentiated after blockade of a 2 -AR by an a 2 -AR antagonist and reached that of isoproterenol, a b-AR agonist. The effect of the non-selective a 2 -AR antagonist phentolamine on the response of the extracellular glycerol concentration (EGC) in AT during two successive bouts of aerobic exercise (50% VO 2max , 60 min duration) was evaluated using the microdialysis method. The metabolic responses measured in perfused probes with Ringer solution were compared to those obtained in perfused probes with Ringer plus 0.1 mmolal phentolamine. Plasma norepinephrine level was not different during the two exercise bouts while that of epinephrine was 2.5-fold higher during the second exercise. EGC in AT was 2-fold higher in the second compared to the ®rst exercise and the same response pattern was found for plasma glycerol. The exerciseinduced increase in EGC was higher in the probe perfused with phentolamine compared to the control probe in both bouts of exercise. However, the potentiating effect of phentolamine on EGC was signi®cant during the second exercise bout but did not reach a signi®cant level during the ®rst. 17 The present study reveals that epinephrine contributes to exercise-induced lipolysis although the existence of a 2 -AR-mediated counteraction was clearly revealed with our protocol. Previous studies using microdialysis have led to con¯icting results. Using local administration of phentolamine, one study in normal subjects has shown that resting lipolysis was modulated by a 2 -adrenergic inhibition whereas the a 2 -adrenergic mechanism did not modulate lipolysis during exercise. 18 Our study demonstrates the physiological relevance of b-and a 2 -AR interplay in the control of lipolysis in subcutaneous adipose tissue during exercise in men. The study suggests for the ®rst time that epinephrine has a speci®c role in vivo in the control of lipolysis in human subcutaneous AT through activation of antilipolytic a 2 -ARs. It also updates numerous in vitro studies which propose that the activation of a 2 -ARs by epinephrine could play an important role in the control of lipolysis in AT, especially in subcutaneous fat deposits.
The second study was performed to see if the physiological activation of antilipolytic a 2 -ARs could be an important inhibitory factor for lipid mobilization in subcutaneous AT in exercising obese subjects, the adipose tissue of which expresses a higher a 2 -AR component in vitro. Using the microdialysis method, we investigated whether the blockade of a 2 -ARs can improve lipolysis in subcutaneous adipose tissue (SCAT) during exercise in healthy young obese and lean men. Changes in extracellular glycerol concentrations and in blood¯ow were measured in SCAT (using microdialysis probes infused with Ringer's solution supplemented with ethanol) at rest and during 60 min exercise bouts at 50% of heart rate reserve. One probe was supplemented with the a 2 -AR antagonist phentolamine. At rest and during exercise, plasma norepinephrine and epinephrine concentrations were not different in the two groups. In the basal state, plasma and extracellular glycerol concentrations were higher, while blood¯ow was lower, in SCAT of obese subjects. During exercise, the greatest increase of plasma glycerol was observed in obese subjects (115AE 35 vs 65 AE 21 mmolal). Conversely, the exercise-induced increase EGC was 5 ± 6 fold lower in obese than in lean subjects (50AE 14 vs Figure 1 Time-course of extracellular glycerol concentration changes in subcutaneous adipose tissue, calculated from dialysate glycerol levels, during 60 min cycle-ergometer exercise in lean and obese subjects. The a 2 -adrenergic receptor antagonist phentolamine was or was not added to the perfusion medium. Data are means AE s.e.m. from seven separate experiments.
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M Lafontan et al 318AE 53 mmolal). The exercise-induced increase in EGC was not signi®cantly modi®ed by phentolamine infusion in lean but was strongly enhanced in the obese subjects and reached the concentrations found in lean subjects (297AE 46 mmolal) (Figure 1 ). The physiological stimulation of SCAT adipocyte a 2 -ARs during exercice-induced SNS activation contributes to the blunted lipolysis noted in obese men. In summary these in vivo results provide evidence, for the ®rst time, of the important contribution played by a 2 -ARs in the physiological impairement of lipolysis in the adipose tissue of obese men. The role of a 2 -ARs may be explored in other fat deposits, in both men and women, in which the adipocytes express a high level of a2-ARs greatly outnumbering that of b-ARs. These ®ndings may have important physiopathologic implications in men developing large subcutaneous fat deposits and women with excessive hip and femoral fat deposits. It is tempting to speculate that adipocyte a 2 -ARs may make a major contribution to the resistance of SCAT to fat loss during very-lowenergy diets and during physical training programmes in obese subjects. Local or oral administration of an a 2 -AR antagonist could represent a possible strategy to facilitate mobilization of SCAT when obese subjects are submitted to periods of exercise.
To conclude, these physiological studies have demonstrated: (1) that epinephrine is involved in the control of lipid mobilization through activation of antilipolytic a 2 -ARs in human subcutaneous AT, during exercise; (2) that a physiological stimulation of adipocyte a 2 -ARs strongly impairs exerciseinduced lipolysis in subcutaneous AT in obese subjects. The blunting of lipid mobilization induced by exercise-induced noradrenaline release is completely suppressed by the local administration of an a 2 -AR antagonist.
Atrial natriuretic peptides and lipolysis regulation in humans
In the search for new additional lipolytic pathways acting in addition to catecholamines, a putative lipolytic effect of natriuretic peptides was investigated in human AT. Atrial natriuretic peptide (ANP) receptors have been described on rodent adipocytes and expression of ANP mRNA found in human AT. ANP and brain natriuretic peptide (BNP) stimulated lipolysis as much as isoproterenol, a non-selective b-AR agonist on isolated human fat cells, whereas C-type natriuretic peptide (CNP) had the lowest lipolytic effect. In situ microdialysis experiments con®rmed the potent lipolytic effect of ANP in abdominal subcutaneous AT of healthy subjects. A high level of ANP binding sites was identi®ed in human adipocytes. The potency order de®ned in lipolysis (ANP b BNP b CNP) and the existence of an ANP-induced cGMP production sustained the presence of type A natriuretic peptide receptors in human fat cells. Activation or inhibition of cGMP-inhibited phosphodiesterase (PDE-3B) and inhibition of adenylyl cyclase activity did not alter ANP-induced lipolysis. The data clearly show that natriuretic peptides are novel activators of human AT lipolysis, operating via a cGMP-dependent pathway which does not involve PDE-3B inhibition and cAMP production. 19 The mechanisms explaining the possible cGMP-dependent activation of hormone-sensitive lipase remain to be demonstrated. It must be remembered that in vitro studies have shown that HSL could be phosphorylated by cGMP-dependent protein kinase. 20 Moreover the results also raise questions about of the physiological andaor pathological role of this new lipolytic pathway.
Conclusions and future trends
Recent data indicate that genetic factors may modify HSL expression andaor activity and the action of catecholamines on lipolysis on fat cells and exert a role in the development of obesity. Altered SNS impact on its target cells could lead to the development of obesity. Reduced ef®ciency of badrenoceptor-dependent lipolysis andaor enhanced a 2 -adrenoceptor-mediated antilipolysis could both impair lipolysis and lead to catecholamine resistance and promote development of obesity. Environmental factors such as a sedentary lifestyle may worsen a hereditary defect affecting b-adrenoceptor-dependent lipolysis while physical exercise may counterbalance the incidence of the hereditary defect. Much information is needed about the disturbances affecting all the steps of the lipolytic cascade and the genetic factors having an effect on these events. Studies associating an approach of the interactions between genetic factors and environmental conditions will be productive in that way.
